E85
Conditions
Interventions
Group 1: Patients with confirmed ATTR-CM who receive a cardiovascular magnetic resonance imaging examination before starting therapy with tafamidis and 9 and 18 months after starting therapy
Sponsors
Deutsches Herzzentrum der Charité
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Diagnosed ATTR-CM according to current standards (TTE, DPD-scintigraphy and/or biopsy) AND: 2. Eligible to receive treatment with Tafamidis 3. Informed consent 4. Agrees to receive note about incidental findings 5. Valid health insurance
Exclusion criteria
Exclusion criteria: 1. Non ATTR-CM 2. Severe cardiovascular comorbidities including: a. Myocardial infarction within the last 6 months b. After coronary stenting with in the last 6 month c. After coronary artery bypass graft (CABG) d. Permanent atrial fibrillation 3. Absolute contraindications for CMR 4. Allergy against gadolinium-containing contrast agent 5. Chronic kidney insufficiency with a GFR <30 ml/min 6. Pregnancy/Breastfeeding 7. No consent to study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Therapy response to tafamidis. Secondarily identifying of quantitative imaging markers and comparing imaging modalities regarding the follow-up and prognostication of these patients. | — |
Secondary
| Measure | Time frame |
|---|---|
| No classical endpoints. | — |
Countries
Germany
Contacts
Public ContactSebastian Spethmann
Deutsches Herzzentrum der Charité
Outcome results
None listed